(Q36605779)

English

An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristics

scientific article published on November 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristics (English)

1 reference

Europe PubMed Central

15 August 2017

phase II clinical trial

0 references

phase III clinical trial

0 references

author name string

Mary Jane Geiger

1

1 reference

Europe PubMed Central

15 August 2017

Zachary Skrivanek

2

1 reference

Europe PubMed Central

15 August 2017

Brenda Gaydos

3

1 reference

Europe PubMed Central

15 August 2017

Jenny Chien

4

1 reference

Europe PubMed Central

15 August 2017

Scott Berry

5

1 reference

Europe PubMed Central

15 August 2017

Donald Berry

6

1 reference

Europe PubMed Central

15 August 2017

publication date

1 November 2012

1 reference

Europe PubMed Central

15 August 2017

Journal of Diabetes Science and Technology

1 reference

Europe PubMed Central

15 August 2017

6

1 reference

Europe PubMed Central

15 August 2017

6

1 reference

Europe PubMed Central

15 August 2017

1319-1327

1 reference

Europe PubMed Central

15 August 2017

Operational challenges and solutions with implementation of an adaptive seamless phase 2/3 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570871

30 September 2017

Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570871

30 September 2017

Exenatide: a review from pharmacology to clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570871

30 September 2017

Resting heart rate in cardiovascular disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570871

30 September 2017

High heart rate: a cardiovascular risk factor?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570871

30 September 2017

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570871

30 September 2017

Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570871

20 September 2018

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570871

20 September 2018

A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570871

20 September 2018

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570871

20 September 2018

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570871

20 September 2018

Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570871

20 September 2018

Secretion of the Incretin Hormones Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide Correlates with Insulin Secretion in Normal Man Throughout the Day

1 reference

https://api.crossref.org/works/10.1177%2F193229681200600610

21 January 2018

Practical modifications of the continual reassessment method for phase I cancer clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/23294776

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23294776

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of a long-acting GLP-1 mimetic (PF-04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/23294776

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/23294776

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets

1 reference

https://pubmed.ncbi.nlm.nih.gov/23294776

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1177/193229681200600610

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36605779&oldid=1640435308"